Literature DB >> 20929925

Copy number increase of aurora kinase A in colorectal cancers: a correlation with tumor progression.

Chao Zhang1, Zhengyu Fang, Yi Xiong, Jiana Li, Li Liu, Manhui Li, Wei Zhang, Jun Wan.   

Abstract

The centrosome-associated kinase aurora A (AURKA) is involved in genetic instability and is over-expressed in several human carcinomas including colorectal cancer (CRC). The choromosome locus of AURKA, 20q13, is frequently amplified in CRC, and the functional impact of such regions needs to be extensively investigated in large amount of clinical samples. Case-matched tissues of colorectal adenocarcinomas and adjacent normal epithelium (n= 134) were included in this study. Quantitative PCR was carried out to examine the copy number and mRNA level of AURKA in CRC. Our results showed that copy number gains of AUKRA were detected in a relative high percentage of CRC samples (32.4%, 43 of 134). There was a positive correlation between copy number increase of AURKA and tumor progression. And copy number gains of AURKA also showed a positive correlation with mRNA over-expression in CRC. However, the expression level of AURKA mRNA was also enhanced in the group of CRC samples with unaltered copy numbers. These findings indicated that sporadic colorectal cancers exhibit different mechanisms of aurora A regulation and this may impact the efficacy of aurora-targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20929925     DOI: 10.1093/abbs/gmq088

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  8 in total

1.  The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.

Authors:  Vikas Sehdev; DunFa Peng; Mohammed Soutto; M Kay Washington; Frank Revetta; Jeffrey Ecsedy; Alexander Zaika; Tilman T Rau; Regine Schneider-Stock; Abbes Belkhiri; Wael El-Rifai
Journal:  Mol Cancer Ther       Date:  2012-02-01       Impact factor: 6.261

2.  A genome-wide study of cytogenetic changes in colorectal cancer using SNP microarrays: opportunities for future personalized treatment.

Authors:  Farzana Jasmine; Ronald Rahaman; Charlotte Dodsworth; Shantanu Roy; Rupash Paul; Maruf Raza; Rachelle Paul-Brutus; Mohammed Kamal; Habibul Ahsan; Muhammad G Kibriya
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

3.  Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer.

Authors:  E Dotan; N J Meropol; F Zhu; F Zambito; B Bove; K Q Cai; A K Godwin; E A Golemis; I Astsaturov; S J Cohen
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

4.  Recombinant human bone morphogenetic protein-2 inhibits gastric cancer cell proliferation by inactivating Wnt signaling pathway via c-Myc with aurora kinases.

Authors:  Kwang Bok Lee; Hua Jin; Shuai Ye; Byung Hyun Park; Soo Mi Kim
Journal:  Oncotarget       Date:  2016-11-08

5.  Amplification and up-regulation of MIR30D was associated with disease progression of cervical squamous cell carcinomas.

Authors:  You Zhou; Yinghua Hao; Yuxia Li; Ruizhen Li; Ruifang Wu; Shubin Wang; Zhengyu Fang
Journal:  BMC Cancer       Date:  2017-03-29       Impact factor: 4.430

6.  Aurora Kinase A Is a Prognostic Marker in Colorectal Adenocarcinoma.

Authors:  Hyun Min Koh; Bo Geun Jang; Chang Lim Hyun; Young Sill Kim; Jin Won Hyun; Weon Young Chang; Young Hee Maeng
Journal:  J Pathol Transl Med       Date:  2016-12-25

7.  Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis.

Authors:  J A C M Goos; V M H Coupe; B Diosdado; P M Delis-Van Diemen; C Karga; J A M Beliën; B Carvalho; M P van den Tol; H M W Verheul; A A Geldof; G A Meijer; O S Hoekstra; R J A Fijneman
Journal:  Br J Cancer       Date:  2013-10-08       Impact factor: 7.640

8.  Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy.

Authors:  Xiaoyu Wu; Wentao Liu; Qinhong Cao; Che Chen; Zhiwei Chen; Zhe Xu; Weisu Li; Fukun Liu; Xuequan Yao
Journal:  J Exp Clin Cancer Res       Date:  2014-01-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.